Bristol-Myers Squibb and Sanofi-Aventis have filed an injunction against Apotex to stop the Canadian drug maker from selling a less expensive, generic version of the blood thinner Plavix. In the filing, the two brand-name makers listed several reasons the injunction should be issued, including the likelihood they will win the pending patent case and that Apotex's launch last week is causing them irreparable harm. They also said they have begun discounting Plavix to stem the loss of the drug's market share.
August 15, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Bristol-Myers Squibb Co. and Sanofi-Aventis SA said Monday they filed an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version of the blood thinner Plavix. They also said they have begun discounting Plavix to stem the loss of the drug’s market share.
A hearing on the motion is set for Friday in the U.S. District Court for the Southern District of New York, where the injunction was filed and a patent case on Plavix is pending.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
